Dose Ranging and Dose Frequency of LIPO-102

A Dose-Ranging and Dose Frequency Study Evaluating the Safety and Efficacy of LIPO-102 for the Reduction of Abdominal Subcutaneous Adipose Tissue

NCT00918814•Neothetics, Inc

View on ClinicalTrials.gov

Summary

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Male or non pregnant female
•Good general health
•Sufficient abdominal fat for injections
•Signed informed consent

Exclusion Criteria

•Known hypersensitivity to study drugs
•Treatment with an investigational agent within 30 days of first dose

Locations (2)

San Diego, California, United States

Baltimore, Maryland, United States

Key Dates

Start Date

June 1, 2009

Primary Completion Date

February 1, 2010

Completion Date

February 1, 2010

Last Updated

March 6, 2015

Enrollment

ACTUAL participants

Conditions

Subcutaneous Adipose Tissue Reduction

Interventions

LIPO-102

DRUG

Placebo

DRUG

Dose Ranging Study

NCT01802723

Periumbilical Subcutaneous Adipose Tissue Reduction

View study

COMPLETEDPHASE1

An Evaluation of the Pharmacokinetics and Safety of LIPO-102 in Healthy Volunteers

NCT00918606

Subcutaneous Adipose Tissue Reduction

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 6, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions